Skip to content

Clinical Efficacy of Using Bioactive Desensitizer Gel

Clinical Efficacy of Using Bioactive Desensitizer Gel Versus Sodium Fluoride Varnish on Cervical Dentin Hypersensitivity in Adult Patients: A 6m Randomized Clinical Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07323693
Enrollment
30
Registered
2026-01-07
Start date
2024-11-20
Completion date
2025-12-20
Last updated
2026-01-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dentin Desensitizing Agents, Dentin Hypersensitivity, Dentin Hypersensitivity, Non-carious Cervical Lesions

Keywords

Dentin hypersentivity

Brief summary

To evaluate and compare the clinical effectiveness of a Bioactive Desensitizer Gel (which releases calcium and phosphate to form hydroxyapatite) versus a standard 5% Sodium Fluoride (NaF) Varnish in reducing cervical dentin hypersensitivity (CDH) in adult patients over a period of 6 months.

Interventions

PROCEDURETreatment

A micro-brush applicator was saturated with the material (Predicta Bioactive Desensitizer Gel) and massaged it into the tooth for 30-40 secs. Using a rubbing motion was used to liquefy the gel and allow it to penetrate the surface

Sponsors

Cairo University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 30 Years
Healthy volunteers
Yes

Inclusion criteria

* • With ≥1 sensitive tooth and with exposed dentin in the upper or lower dental arches. * Grade IV gingival recession. * Schiff sensitivity score needed to be ≥2, indicating that application of a jet of air makes the patient respond and move or requests discontinuation of the stimuli application.

Exclusion criteria

* • Domestic or in-office fluoride application and bleaching 6 months before beginning of treatment * Long-term use of anti-inflammatory, analgesic and psychotropic drugs. * Allergies to product ingredients * Eating disorders, systemic conditions that cause or predispose patients to develop dentin hypersensitivity (for example, gastroesophageal reflux disease, GERD) * Excessive dietary or environmental exposure to acids. * Orthodontic appliance treatment within the previous three months. * Periodontal surgery within the previous three months before the study

Design outcomes

Primary

MeasureTime frameDescription
Visual analog scale (VAS)Change from the Baseline, 1 week, 1 months, 3 months, 6 monthsA VAS is a line that is 10 cm in length, the extremes of which represent the limits of pain, a patient may experience an external stimulus (The left endpoint designated no pain was marked as 0 and the right endpoint designated sever pain was marked as 10). Patients will be asked to place a mark on the 10 cm line that indicated their dentin hypersensitivity intensity

Secondary

MeasureTime frameDescription
Level of Pain Assessment using The Schiff sensitivity scaleChange from the Baseline, 1 week, 1 months, 3 months, 6 monthsIt was used to assess dentin hypersensitivity. A score of 0, 1, 2 or 3 was assigned 0 = no subject response to stimulus 1. = subject response but will continue 2. = subject responds and moves or requests discontinuation 3. = painful response to stimulus, discontinuation requested.

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026